Clinical Trial

Study of AHB-137 in Participants With Chronic Hepatitis B (CHB) Treated With Nucleos(t)Ide Analogues (NAs)(AUSHINE)

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study is a randomized, double-blind, multicenter phase 3 clinical trial to evaluate the efficacy and safety of AHB-137 injection in participants with HBeAg-negative CHB treated with NAs.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-11-21; most recent amendment 2026-05-01.
Status change: Recruiting → Active, Not Recruiting 2025-12-17
Trial Details
NCT Number NCT07246889
Lead Sponsor Ausper Biopharma Co., Ltd.
Conditions Chronic Hepatitis B
Enrollment 577 participants
Start Date 2025-08-12
Primary Completion 2026-12-18 (estimated)
Study Completion 2027-10-31 (estimated)
Updated on ClinicalTrials.gov 2026-05-04